DiaMedica Therapeutics Valuation
DMAC Stock | USD 2.37 0.02 0.84% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. DiaMedica Therapeutics shows a prevailing Real Value of $3.77 per share. The current price of the firm is $2.37. Our model computes the value of DiaMedica Therapeutics from reviewing the firm fundamentals such as Shares Outstanding of 37.96 M, current valuation of 37.47 M, and Shares Owned By Insiders of 31.17 % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will submerge. Key fundamental drivers impacting DiaMedica Therapeutics' valuation include:
Price Book 1.8029 | Enterprise Value 37.5 M | Enterprise Value Ebitda (1.86) |
Undervalued
Today
Please note that DiaMedica Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of DiaMedica Therapeutics is based on 3 months time horizon. Increasing DiaMedica Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for DiaMedica Therapeutics is useful when determining the fair value of the DiaMedica stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of DiaMedica Therapeutics. Since DiaMedica Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DiaMedica Stock. However, DiaMedica Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 2.37 | Real 3.77 | Target 8.33 | Hype 2.34 |
The real value of DiaMedica Stock, also known as its intrinsic value, is the underlying worth of DiaMedica Therapeutics Company, which is reflected in its stock price. It is based on DiaMedica Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of DiaMedica Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence DiaMedica Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of DiaMedica Therapeutics helps investors to forecast how DiaMedica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DiaMedica Therapeutics more accurately as focusing exclusively on DiaMedica Therapeutics' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use DiaMedica Therapeutics' intrinsic value based on its ongoing forecasts of DiaMedica Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against DiaMedica Therapeutics' closest peers. When choosing an evaluation method for DiaMedica Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
DiaMedica Therapeutics Investments |
|
DiaMedica Valuation Drivers Correlation
Many accounts on the financial statements of DiaMedica Therapeutics are highly interrelated and sometimes correlated. Consequently, when conducting DiaMedica's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of DiaMedica
Click cells to compare fundamentals
DiaMedica Valuation Trend
Knowing DiaMedica Therapeutics' actual value is paramount for traders to make sound investment determinations. DiaMedica Therapeutics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of DiaMedica Therapeutics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both DiaMedica Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
DiaMedica Market Cap
DiaMedica Therapeutics is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 7.23 Billion. DiaMedica Therapeutics claims roughly 89.96 Million in market capitalization contributing just under 2% to equities under Health Care industry.DiaMedica Therapeutics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining DiaMedica Therapeutics's current stock value. Our valuation model uses many indicators to compare DiaMedica Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DiaMedica Therapeutics competition to find correlations between indicators driving DiaMedica Therapeutics's intrinsic value. More Info.DiaMedica Therapeutics is rated below average in price to earning category among related companies. It is rated below average in price to book category among related companies . As of April 17, 2024, Price To Book Ratio is expected to decline to 1.72. Comparative valuation analysis is a catch-all model that can be used if you cannot value DiaMedica Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DiaMedica Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DiaMedica Therapeutics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates DiaMedica Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in DiaMedica Therapeutics and how it compares across the competition.
About DiaMedica Therapeutics Valuation
The stock valuation mechanism determines the current worth of DiaMedica Therapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of DiaMedica Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of DiaMedica Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing DiaMedica Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of DiaMedica Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of DiaMedica Therapeutics. We calculate exposure to DiaMedica Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to DiaMedica Therapeutics's related companies.Last Reported | Projected for Next Year | ||
Gross Profit | -30 K | -28.5 K | |
Pretax Profit Margin | (10.18) | (10.69) | |
Operating Profit Margin | (12.17) | (12.78) | |
Net Loss | (10.32) | (10.84) | |
Gross Profit Margin | 0.00 | 0.00 |
8 Steps to conduct DiaMedica Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates DiaMedica Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct DiaMedica Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain DiaMedica Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine DiaMedica Therapeutics' revenue streams: Identify DiaMedica Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research DiaMedica Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish DiaMedica Therapeutics' growth potential: Evaluate DiaMedica Therapeutics' management, business model, and growth potential.
- Determine DiaMedica Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate DiaMedica Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
DiaMedica Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as DiaMedica Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding | 32.6 M |
DiaMedica Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of DiaMedica Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value DiaMedica we look at many different elements of the entity such as DiaMedica's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. DiaMedica Therapeutics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final DiaMedica Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as DiaMedica Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use DiaMedica Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes DiaMedica Therapeutics' worth.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Return On Assets (0.30) | Return On Equity (0.47) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.